Journal article
Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial
Daron G Ferris, Darron R Brown, Anna R Giuliano, Evan Myers, Elmar A Joura, Suzanne M Garland, Susanne K Kjaer, Gonzalo Perez, Alfred Saah, Alain Luxembourg, Christine Velicer
Papillomavirus Research | ELSEVIER | Published : 2020
Abstract
OBJECTIVES: The natural history of human papillomavirus (HPV) infection has been studied extensively in young women; this study investigated HPV infection in adult women. METHODS: Data from 3817 women aged 24-45 years in a global trial of the 4-valent HPV (6/11/16/18) vaccine were used to calculate prevalence of anogenital infections containing 9-valent (9v) HPV vaccine types (6/11/16/18/31/33/45/52/58) and five non-vaccine types (35/39/51/56/59). Incidence of infections and persistent infections was estimated for 989 placebo recipients naive to all 14 HPV types at baseline. Age-adjusted hazard ratios were calculated for various sociodemographic factors. RESULTS: Prevalence of anogenital inf..
View full abstractGrants
Funding Acknowledgements
Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. This study was designed, managed, and analyzed jointly by authors employed by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. and external authors who were not paid for their work. Medical writing assistance was provided by ApotheCom (New York, NY, USA) and was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.